Zhejiang Jingxin Pharmaceutical Co., Ltd.
京新药业
002020
Shenzhen Stock Exchange
Company Profile
Integrated active pharmaceutical ingredient-formulation, creating cost advantages, and strengthening supply capabilities: Currently, most of the company's finished products are produced with integrated active pharmaceutical ingredients, and it continuously extends upstream to achieve self-supply of key intermediates. It continuously improves its industrial layout to provide stable supply capabilities for the hospital market after centralized procurement. Guided by market and clinical value, striving for a "combination of innovation and generic drugs" approach: Focusing on mental and neurological health and cardiovascular and cerebrovascular health, the company promotes the simultaneous development of innovative drugs and generic drugs, enriching the product pipeline continuously and providing a source of power for the company's sustainable development. Continuous improvement of service capabilities, driving market upgrades: Leveraging its strong oral solid formulation technology transfer capabilities and high-quality commercial delivery experience, the company actively introduces domestic and foreign formulation outsourcing business to expand growth opportunities for its formulation business. It strengthens the construction of its active pharmaceutical ingredient product access capability, actively expands the mainstream market, and continuously enhances its international customer's active ingredient supply service capability. BEACON continually improves its research and development, lean manufacturing, and system integration capabilities, building core competitiveness in product capabilities and comprehensive delivery capabilities. Balancing in-hospital and out-of-hospital, persisting in building marketing capabilities: As healthcare reform continues to deepen and centralized procurement policies advance, the company actively responds to market changes, strengthens the top-level design of its sales architecture, establishes two major business units—hospitals and retail, and bases itself in hospitals while expanding outside hospitals. It promotes multi-channel coordinated development and advances marketing capability construction and enhancement.
Full description
Zhejiang Jingxin Pharmaceutical Co., Ltd. (Stock Code: 002020) is a pharmaceutical public company that integrates research and development, production, and sales. The company follows the business policy of "strengthening the pharmaceutical core business and developing medical devices," adheres to the core values of "pragmatism, innovation, inclusiveness, and win-win," and has a mission to "carefully safeguard health." It is committed to becoming a leader in the fields of mental and neurological health as well as cardiovascular and cerebrovascular health in China. The company has a registered capital of 860 million RMB, total assets of 8.48 billion RMB, two headquarters (Xinchang and Hangzhou), seven production bases (Xinchang, Shangyu, Shangrao, Inner Mongolia, Shenzhen, Shenyang, Zhongshan), one breeding base (Dali), three research and development bases (Xinchang, Shanghai, Hangzhou), and investments in the construction of the Shandong Weifang full-industry chain production base and the Jingxin Xinchang International Health Industry Park project. The company is primarily engaged in the research, production, and sales of active pharmaceutical ingredients, chemical formulations, traditional Chinese medicine, biologics, and medical devices. Chemical formulations are the company's largest business segment, covering treatments for mental and neurological disorders, cardiovascular diseases, and digestive disorders. In the mental and neurological field, the company's products such as Levetiracetam tablets, Sertraline hydrochloride tablets/disintegrating tablets, and Paroxetine hydrochloride tablets/extended-release tablets are among the top-selling products in the national hospital market. In the cardiovascular field, Rosuvastatin calcium tablets/disintegrating tablets, Simvastatin tablets, and Pitavastatin calcium disintegrating tablets have all passed consistency evaluations and entered national or provincial alliance procurement programs. In the digestive field, Kangfuxin liquid and Lactobacillus rhamnosus live capsule have shown clear efficacy and have a good competitive position, with increasing market influence. The company focuses on market and clinical value, planning its research and development pipeline and product gradient layout rationally around the two strategic areas of mental and neurological health and cardiovascular and cerebrovascular health. The first innovative drug, Dutaserpin capsules,approved for listing, and more than ten innovative drug (device) projects and over 20 generic drug projects are progressing systematically. The company is one of the major global manufacturers of quinolone antibacterial active pharmaceutical ingredients, with its main products Levofloxacin and Ciprofloxacin having a leading production volume and market share worldwide. The company continuously extends its reach upstream and downstream, producing specialty active pharmaceutical ingredients such as Simvastatin, Rosuvastatin calcium, Sertraline hydrochloride, and Levetiracetam, continuously building its advantage in active pharmaceutical ingredient-formulation integration. Currently, most of the company's products are produced with integrated raw materials and formulations. The wholly-owned subsidiary BEACON is a medical device company that provides solutions in the field of medical imaging displays. It has a market share of over 50% in the domestic medical imaging display terminal market and is a strategic partner of major global equipment manufacturers, holding a leading position in the market. BEACON always focuses on supporting market sales, continuously improving product capabilities, optimizing integrated supply chains, and building core competitiveness in product capabilities and comprehensive delivery capabilities to provide customers with system solutions. Over the years, the company has received numerous social honors and recognitions, including being one of the first "Leading Chinese Pharmaceutical Enterprises in Internationalization of Formulations," and consistently ranking among the "Outstanding Export Brands of Chinese Chemical Pharmaceutical Industry," "Top 100 Chinese Pharmaceutical Industry Enterprises," and "Top 100 Chinese Chemical Pharmaceutical Enterprises."